New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
Total investment incurred for setting up the new R&D Rs 250 crore
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
Subscribe To Our Newsletter & Stay Updated
